Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Intravenous Immune Globulin Therapy for Neurologic Diseases
Ann Int Med 126:721-730, Dalakas,M.C., 1997
Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994
Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System
Ann Neurol 91:756-771, Frontera, J.A.,et al, 2022
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer
J Gerontol Geriatr Res 5:3, Sabeeh-Ur-Rehman, B. & Bhaumik, S., 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Association between Guillain-Barr� Syndrome and Influenza a (H1N1) 2009 Monovalent Inactivated Vaccines in the USA: A Meta-Analysis
Lancet 381:1461-1468, Salmon, D.,et al, 2013
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Neurologic Adverse Events Associated With Smallpox Vaccination in the United States, 2002-2004
JAMA 294:2744-2750, Sejvar,J.J.,et al, 2005
Adverse Events Reported Following Live, Cold-Adapted, Intranasal Influenza Vaccine
JAMA 294:2720-2725, Izurieta,H.S.,et al, 2005
Guillain-Barre Syndrome Seen in Users of Isotretinoin
BMJ 328:1537, Pritchard,J.,et al, 2004
Guillain-Barre Syndrome Follwoing Influenza Vaccination
JAMA 292:2478-2481, Haber,P.,et al, 2004
An Acute Neurologic Syndrome Temporally Associated with Postexposure Trtm of Rabies
Pediatrics 100:720-721, Mortiere,M.D.&Falcone,A.L., 1997
Reversible Encephalopathy with Cerebral Vasospasm in a Guillain-Barre Syndrome Patient Treated with Intravenous Immunoglobulin
Neurol 46:250-251, Voltz,R.,et al, 1996
Pilot Trial of Immunoglobulin Versus Plasma Exchange in Patients with Guillain-Barre Syndrome
Neurol 46:100-103, Bril,V.,et al, 1996
Intravenous IgG in Guillain-Barre Syndrome
BMJ 313:376-377, Hughes,R.A.C., 1996
Relapse in Guillain-Barre Syndrome after Treatment with Human Immune Globulin
Neurol 43:872-875, 8571993., Inrani,D.N.,et al, 1993
Human Immune Globulin Infusion in Guillain-Barre Syndrome:Worsening During & After Treatment
Neurol 43:1034-1036, 8571993., Castro,L.H.M.&Ropper,A.H., 1993
Guillain-Barre Syndrome after Exogenous Gangliosides in Italy
BMJ 307:1463-1464, Landi,G.,et al, 1993
GM-1 Ganglioside for Spinal-Cord Injury
NEJM 326:493, Schonhofer,P.S., 1992
Bovine Gangliosides and Acute Motor Polyneuropathy
BMJ 305:1330-1331, Figueras,A.,et al, 1992
Guillain-Barre Syndrome After Streptokinase Therapy
Acta Neurologica Scand 82:153, Roquer,J.,et al, 1990
Postmarketing Surveillance for Neurologic Adverse Events after Hepatitis B Vaccination, Exp of the First 3 Yrs
Am J Epidemiol 127:337-352, Shaw,F.E.,et al, 1988
Neuroleptic Malignant Syndrome
NEJM 391:1130-1138, Wijdicks,E.F.M. & Ropper,A.H., 2024
Cannabis-Related Disorders and Toxic Effects
NEJM 389: 2267-2275, Gorelick,D.A., 2023
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
The Dangers of PRES
Neurol 92:e282-e285, Chaterine, C.,et al, 2019
Reversible Cerebral Vasoconstriciton Syndrome
www.UptoDate.com, June, Singhal, A., 2019
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018
Tocilizumab Treatment for New Onset Refractory Status Epilepticus
Ann Neurol 84:940-945, Jun, J.,et al, 2018
Inflammatory Demyelinating Polyneuropathy Versus Leptomeningeal Disease Following Ipilimumab
J Immunother Cancer 6:11, Cafuir, L.,et al, 2018
A 35-Year-Old Man with 2 Episodes of Meningoencephalitis Associated with Flu-Like Illness
Neurol 84:e60-e64, Lewis, S.L., 2015
Anesthetic Drugs in Status Epilepticus: Risk or Rescue?
Neurol 82:656-664, Sutter, R.,et al, 2014
Drug Treatment of Epilepsy in Adults
BMJ 348:g2546, Schmidt, D. & Schachter, S.C., 2014
Utility of an Immunotherapy Trial in Evaluating Patients with Presumed Autoimmune Epilepsy
Neurol 82:1578-1586, Toledano, M.,et al, 2014
Tumefactive MS Lesions under Fingolimod
Neurol 81:1654-1658, Pilz, G.,et al, 2013
Botulinum Toxin A for Prophylactic Treatment of Migraine and Tension Headaches in Adults
JAMA 307:1736-1745, Jackson,J.L.,et al, 2012
Multimodal Imaging of Reversible Cerebral Vasoconstriction Syndrome: A Series of 6 Cases
AJNR 33:1403-1410, Marder, C.P.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Neuro-Sweets Disease
Pract Neurol 12:126-130, Maxwel,G.,et al, 2012
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011